secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001493152-24-024661
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Provectus shareholders approve reverse stock split authorization and other proposals at annual meeting
--------------------------------------------------------------------------------

- All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.
- Reverse stock split (1:10 to 1:50) authorized with 302.9M for (92.4%); authorized share reduction also approved.
- Advisory vote on executive compensation passed with 202.8M for (96.6%); broker non-votes 115.0M.
- Marcum LLP ratified as auditor for 2024 with 325.7M for (99.6%); no broker non-votes.
- 2024 Equity Compensation Plan approved with 198.3M for (94.0%); broker non-votes 115.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/0001493152-24-024661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer